US2005148512A1PendingUtilityA1

Medical implants and fibrosis-inducing agents

58
Assignee: ANGIOTECH INT AGPriority: Nov 10, 2003Filed: Nov 10, 2004Published: Jul 7, 2005
Est. expiryNov 10, 2023(expired)· nominal 20-yr term from priority
Inventors:William L. HunterDavid GravettPhilip M. ToleikisArpita MaitiPierre SignoreRichard Liggins
A61P 9/00A61P 43/00A61B 17/12168A61L 31/16A61L 2300/00A61B 17/1219A61F 2250/0067A61K 38/4833A61B 17/1214A61P 1/00A61L 27/54A61B 17/68A61B 17/12022A61B 17/12099A61B 17/12109A61B 17/11A61P 19/00A61L 2430/38A61K 38/38A61B 17/12186A61L 2300/412A61K 38/39A61K 38/363A61K 45/06
58
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Implants are used in combination with a fibrosis-inducing agent in order to induce fibrosis that may otherwise not occur when the implant is placed within an animal or increase fibrosis between the implant and the host tissue.

Claims

exact text as granted — not AI-modified
1 . A method comprising introducing into an intervertebral disc space of a patient in need thereof, a therapeutically effective amount of a fibrosing agent or a composition comprising a fibrosing agent, where the fibrosing agent induces a fibrotic response at the intervertebral disc space of the patient, thereby providing the patient with a beneficial result.  
     
     
         2 - 5 . (canceled)  
     
     
         6 . The method of  claim 1  wherein the fibrosing agent promotes angiogenesis.  
     
     
         7 . The method of  claim 1  wherein the fibrosing agent promotes fibroblast migration.  
     
     
         8 . The method of  claim 1  wherein the fibrosing agent promotes fibroblast proliferation.  
     
     
         9 . The method of  claim 1  wherein the fibrosing agent promotes deposition of extracellular matrix (ECM).  
     
     
         10 . The method of  claim 1  wherein the fibrosing agent promotes tissue remodeling.  
     
     
         11 . The method of  claim 1  wherein the fibrosing agent is an arterial vessel wall irritant.  
     
     
         12 . The method of  claim 1  wherein the fibrosing agent is or comprises silk.  
     
     
         13 . The method of  claim 1  wherein the fibrosing agent is or comprises silkworm silk.  
     
     
         14 . The method of  claim 1  wherein the fibrosing agent is or comprises spider silk.  
     
     
         15 . The method of  claim 1  wherein the fibrosing agent is or comprises recombinant silk.  
     
     
         16 . The method of  claim 1  wherein the fibrosing agent is or comprises raw silk.  
     
     
         17 . The method of  claim 1  wherein the fibrosing agent is or comprises hydrolyzed silk.  
     
     
         18 . The method of  claim 1  wherein the fibrosing agent is or comprises acid-treated silk.  
     
     
         19 . The method of  claim 1  wherein the fibrosing agent is or comprises acylated silk.  
     
     
         20 - 23 . (canceled)  
     
     
         24 . The method of  claim 1  wherein the fibrosing agent is or comprises talc.  
     
     
         25 . The method of  claim 1  wherein the fibrosing agent is or comprises chitosan.  
     
     
         26 . The method of  claim 1  wherein the fibrosing agent is or comprises polylysine.  
     
     
         27 . The method of  claim 1  wherein the fibrosing agent is or comprises fibronectin.  
     
     
         28 . The method of  claim 1  wherein the fibrosing agent is or comprises bleomycin.  
     
     
         29 . The method of  claim 1  wherein the fibrosing agent is or comprises CTGF.  
     
     
         30 - 47 . (canceled)  
     
     
         48 . The method of  claim 1  wherein the composition further comprises an agent that promotes bone growth.  
     
     
         49 . The method of  claim 48  wherein the fibrosing agent that promotes bone growth is a bone morphogenic protein.  
     
     
         50 . The method of  claim 48  wherein the fibrosing agent that promotes bone growth is an osteogenic growth factor.  
     
     
         51 . The method of  claim 50  wherein the osteogenic growth factor is selected from transforming growth factor, platelet-derived growth factor, and fibroblast growth factor.  
     
     
         52 . The method of claim I wherein the composition further comprises a pharmaceutical agent that induces sclerosis (a sclerosant).  
     
     
         53 . The method of  claim 52  wherein the sclerosant is selected from the group consisting of ethanol, dimethyl sulfoxide, sucrose, sodium chloride, dextrose, glycerin, minocycline, tetracycline, doxycycline, polidocanol, sodium tetradecyl sulfate, sodium morrhuate, and sotradecol.  
     
     
         54 . (canceled)  
     
     
         55 . The method of claim I wherein the composition further comprises an inflammatory cytokine.  
     
     
         56 . The method of  claim 55  wherein the inflammatory cytokine is selected from the group consisting of TGFβ, PDGF, VEGF, bFGF, TNFα, NGF, GM-CSF, IGF-a, IL-1, IL-1-β, IL-8, IL-6, and growth hormone.  
     
     
         57 . The method of  claim 1  wherein the composition further comprises an agent that stimulates cell proliferation.  
     
     
         58 - 7018 . (canceled)  
     
     
         7019 . A medical device comprising a spinal fusion device and a fibrosing agent, where the fibrosing agent induces a fibrotic response between the device and a patient in which the device is implanted.  
     
     
         7020 . (canceled)  
     
     
         7021 . The device of  claim 7019  wherein the fibrosing agent promotes angiogenesis.  
     
     
         7022 . The device of  claim 7019  wherein the fibrosing agent promotes fibroblast migration.  
     
     
         7023 . The device of  claim 7019  wherein the fibrosing agent promotes fibroblast proliferation.  
     
     
         7024 . The device of  claim 7019  wherein the fibrosing agent promotes deposition of extracellular matrix (ECM).  
     
     
         7025 . The device of  claim 7019  wherein the fibrosing agent promotes tissue remodeling.  
     
     
         7026 . The device of  claim 7019  wherein the fibrosing agent is an arterial vessel wall irritant.  
     
     
         7027 . (canceled)  
     
     
         7028 . (canceled)  
     
     
         7029 . The device of  claim 7019  wherein the fibrosing agent is or comprises silk.  
     
     
         7030 . (canceled)  
     
     
         7031 . The device of  claim 7019  wherein the fibrosing agent is or comprises chitosan.  
     
     
         7032 . The device of  claim 7019  wherein the fibrosing agent is or comprises polylysine.  
     
     
         7033 . The device of  claim 7019  wherein the fibrosing agent is or comprises fibronectin.  
     
     
         7034 . The device of  claim 7019  wherein the fibrosing agent is or comprises bleomycin.  
     
     
         7035 . The device of  claim 7019  wherein the fibrosing agent is or comprises CTGF.  
     
     
         7036 - 7090 . (canceled)  
     
     
         7091 . The device of  claim 7019 , further comprising a second pharmaceutically active agent.  
     
     
         7092 . (canceled)  
     
     
         7093 . The device of  claim 7019 , further comprising an agent that inhibits infection.  
     
     
         7094 - 9860 . (canceled)  
     
     
         9861 . A method of making a medical device comprising combining i) a spinal fusion implant, with ii) a fibrosing agent or a composition comprising a fibrosing agent, where the fibrosing agent induces a fibrotic response between the device and a patient in which the device is implanted.  
     
     
         9862 . (canceled)  
     
     
         9863 . The method of  claim 9861  wherein the fibrosing agent promotes angiogenesis.  
     
     
         9864 . The method of  claim 9861  wherein the fibrosing agent promotes fibroblast migration.  
     
     
         9865 . The method of  claim 9861  wherein the fibrosing agent promotes fibroblast proliferation.  
     
     
         9866 . The method of  claim 9861  wherein the fibrosing agent promotes deposition of extracellular matrix (ECM).  
     
     
         9867 . The method of  claim 9861  wherein the fibrosing agent promotes tissue remodeling.  
     
     
         9868 . The method of  claim 9861  wherein the fibrosing agent is an arterial vessel wall irritant.  
     
     
         9869 . (canceled)  
     
     
         9870 . (canceled)  
     
     
         9871 . The method of  claim 9861  wherein the fibrosing agent is or comprises silk.  
     
     
         9872 . (canceled)  
     
     
         9873 . The method of  claim 9861  wherein the fibrosing agent is or comprises chitosan.  
     
     
         9874 . The method of  claim 9861  wherein the fibrosing agent is or comprises polylysine.  
     
     
         9875 . The method of  claim 9861  wherein the fibrosing agent is or comprises fibronectin.  
     
     
         9876 . The method of  claim 9861  wherein the fibrosing agent is or comprises bleomycin.  
     
     
         9877 . The method of  claim 9861  wherein the fibrosing agent is or comprises CTGF.  
     
     
         9878 . The method of  claim 9861  wherein the fibrosing agent is in the form of a thread, or is in contact with a thread.  
     
     
         9879 - 9930 . (canceled)  
     
     
         9931 . The method of  claim 9861 , wherein the implant is further combined with a second pharmaceutically active agent.  
     
     
         9932 . (canceled)  
     
     
         9933 . The method of  claim 9861  wherein the implant is further combined with an agent that inhibits infection.  
     
     
         9934 - 10247 . (canceled)

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.